D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease (within tumor margins) after surgery, followed by later repeated injections of 2141-V11 in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adults newly diagnosed with a type of cancerous brain tumor called glioblastoma. The word "investigational" means the study drugs are still being tested in research studies and are not approved by the U.S. Food and Drug Administration (FDA).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Nowo rozpoznany glejiak wielopostaciowy z pozostałością guza widoczną w badaniu MRI po operacji i chemioterapii
- •Pozostałość guza o wielkości nie większej niż 3 cm
- •Ukończona standardowa terapia (radioterapia i chemioterapia)
- •Zdolność do wykonania badania MRI mózgu
- •Odpowiednie wyniki badań krwi (hemoglobina, płytki krwi, wskaźniki wątroby i nerek)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Duke University Medical Center
Durham, United States
Trial contact
Daniel Landi, MD
Stevie Threatt
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.